Implant for deep sclerectomy

• US 6,383,219 B1
• Filed: 08/12/1999
• Issued: 05/07/2002
• Est. Priority Date: 02/17/1997
• Status: Expired due to Fees

• Current Assignee: Corneal Industrie
• Original Assignee: Corneal Industrie
• Inventors: Sourdille, Philippe, Jallet, Valérie, Bos, Gilles, Telandro, Alain, Villain, Franck
• Primary Examiner(s): Willse, David H.
• Application Number:
  US09/367,421
• Time in Patent Office: 999 Days
• Field of Search: 623/4.1, 623/5.11, 623/5.16, 623/905, 623/906, 623/915, 623/924-926, 604/8
• US Class Current: 623/4.1
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002

Abstract

The invention concerns an implant for deep sclerectomy for draining aqueous humor during surgical treatment of glaucoma. The implant is made of crosslinked hyaluronic acid and has substantially the shape of a polyhedron with at least five faces, advantageously the shape of a polyhedron with five or six faces. In a preferred embodiment, the implant has substantially the shape of a prism, advantageously straight with a trapezoidal base.

Claims

1. An implant for deep sclerectomy, intended to drain the aqueous humor, made of crosslinked hyaluronic acid and presenting substantially the shape of a polyhedron with at least five faces wherein at least one face is structured to direct flow of the aqueous humor.

2. The implant of claim 1, wherein it presents substantially the shape of a polyhedron with five or six faces.

3. The implant of claim 1, wherein it presents substantially the shape of a convex polyhedron;

said convex polyhedron having at least a substantially plane base which presents at least 3 sides and a small thickness;

said thickness being defined as the maximum distance between said base and an apex opposite or a face opposite said base.

4. The implant of claim 3, wherein said thickness is included between {fraction (1/12)}th and ¼

of the length of the largest side of said base.

5. The implant of claim 3, wherein said base has a triangular or trapezoidal shape.

6. The implant of claim 3, wherein said base is slightly incurved so that, once the implant is positioned, it follows a radius of curvature of the eye.

7. The implant of claim 1, wherein it presents substantially the shape of a prism with trapezoidal base.

8. The implant of claim 7, wherein it presents substantially the shape of a straight prism with trapezoidal base.

9. The implant of claim 1, wherein its apices are blunt.

10. The implant of claim 1, wherein said hyaluronic acid has been crosslinked, via its hydroxyl functions, by means of a crosslinking agent presenting reactive functions;

said agent intervening in quantities such that the ratio;

total number of reactive functions of said crosslinking agent/total number of disaccharidic repeating units of the molecules of hyaluronic acid, is included between 0.2 and 1.

11. The implant of claim 10, wherein said reactive functions of said crosslinking agent are epoxy functions.

12. The implant of claim 1, wherein said crosslinked hyaluronic acid has at least one active principle incorporated therein.

13. The implant of claim 1, wherein its thickness is about 2 mm.

14. A method for treating glaucoma according to the surgical technique of deep sclerectomy carried out with an implant, said method comprising

incising the sclera until plumb with Schlemm'"'"'s canal to generate a cavity in the deep scleral bed,

inserting in said cavity an implant, wherein said implant is made of crosslinked hyaluronic acid and presents substantially the shape of a polyhedron with at least five faces.

15. The method of claim 14, wherein said implant presents substantially the shape of a polyhedron with five or six faces.

16. The method of claim 14, wherein said implant presents substantially the shape of a convex polyhedron;

said convex polyhedron having at least a substantially plane base which presents at least 3 sides and small thickness;

said thickness being defined as the maximum distance between said base and an apex opposite or a face opposite said base.

17. The method of claim 16, wherein said thickness is included between {fraction (1/12)}th and ¼

of the length of the largest side of said base.

18. The method of claim 16, wherein said base has a triangular or trapezoidal shape.

19. The method of claim 16, wherein said base is slightly incurved so that, once the implant is positioned, it follows a radius of curvature of the eye.

20. The method of claim 14, wherein said implant presents substantially the shape of a prism with trapezoidal base.

21. The method of claim 20, wherein said implant presents substantially the shape of a straight prism with trapezoidal base.

22. The method of claim 14, wherein the apices of said implant are blunt.

23. The method of claim 14, wherein said hyaluronic acid has been crosslinked, via its hydroxyl functions, by means of a crosslinking agent presenting reactive functions;

said agent intervening in quantities such that the ratio;

total number of reactive functions of said crosslinking agent/total number of disaccharidic repeating units of the molecules of hyaluronic acid, is included between 0.2 and 1.

24. The method of claim 23, wherein said reactive functions of said crosslinking agent are epoxy functions.

25. The method of claim 14, wherein said crosslinked hyaluronic acid has at least one active principle incorporated therein.

26. A deep sclerectomy implant made of crosslinked hyaluronic acid having substantially the pre-formed shape of a polyhedron with at least five faces and a thickness of about 2 mm, wherein at least one face is structured to direct flow of the aqueous humor.

27. A method for reducing the intra-ocular pressure in the eye of a mammalian patient, comprising:

incising the sclera of an eye until plumb with Schlemm'"'"'s canal to generate a cavity in the deep scleral bed, and

inserting an implant in said cavity, wherein said implant is made of crosslinked hyaluronic acid having substantially the shape of a polyhedron with at least five faces, to allow increased aqueous humor outflow from the anterior chamber of the eye, and reduce the intraocular pressure.